Practical consensus recommendations for polytherapy involving stiripentol in Dravet syndrome: A nominal group approach - PubMed
3 hours ago
- #consensus-recommendations
- #Dravet syndrome
- #stiripentol
- Dravet syndrome (DS) is a drug-resistant developmental and epileptic encephalopathy requiring multiple antiseizure medications (ASMs).
- Therapeutic management is complex, involving DS-specific agents (stiripentol, cannabidiol, fenfluramine), non-specific ASMs, and non-pharmacologic options.
- A consensus initiative was developed to guide clinicians in managing DS, focusing on stiripentol (STP)-containing regimens.
- 38 statements across six themes were developed by experts and rated by an international panel of 59 clinicians.
- 34 out of 38 statements reached consensus, emphasizing family involvement, polytherapy management, and adverse event monitoring.
- The consensus integrates evidence and clinical expertise to address gaps in DS polytherapy management.